On the upside, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will test short term resistance at around $2.43. On a downside, the share price is likely to find some support, which begins at $1.62. The failure to get near-term support could push it to $1.31. Its 50 day simple moving average (SMA 50) price is $4.79 and its 200-day simple moving average (SMA 200) price is $4.7. The company’s stock currently has a total float of 29.15M shares. Its weekly volatility is hovering around 13.93% and felt 9.89% volatility in price over a month.
CNAT stock has been range bound between the range of $1.8 and $1.8 during the whole day. The stock finished Thursday at $1.94. The -56.89% downtrend forced its market value to reach at $60.94M. The price went up as high as $1.8 before retreating. Trading activity significantly improved as the volume at ready counter increased to 8,799,152 shares versus 904,865 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 641,173 shares. The stock is now -39.75% above against its bear-market low of $3.22 on December 06, 2018. It has retreated -309.79% since it’s 52-week high of $7.95 reached in March. Now the market price is down -52.8% on the year and down -58.01% YTD.
Separately, it has been reported that multiple insider activity took place at Conatus Pharmaceuticals Inc. (CNAT). Director Kisner Daniel L acquired 4,000 shares for $7,145 in transaction occurred on 2015/04/08. After making this transaction, the Director owns a direct stake of 23,000 shares, worth $13,861, as per the last closing price. On 2013/07/30 Scopa James Paul, Director at CNAT, purchased 165,265 shares at an average price of $11 per share. The new stake is valued at $2,312,635.
10% Owner, Evnin Luke had invested in 165,265 shares for $1,192,080 through a trade on 2013/07/30. Following this activity, the insider holds 1,817,915 shares worth $2,312,635 as of recent close. Wall Street’s most bullish Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) analysts are predicting the share price to blow past $20 per share during the next 12 months. The current median share price forecast by them is $15, suggesting that the stock could increase 673.2% in that time frame. The average price target of $15.8 calls for a nearly 714.43% increase in the stock price.
It had seen a negative analyst call from Stifel, which downgraded the stock from Buy to Hold on December 06. Analysts at ROTH Capital, started covering the stock on February 08 with a Buy rating. Brokerage firm H.C. Wainwright, looks cautious as they stick to prior recommendation of Buy, in a call on November 02. However, they did change the target price from $18 to $17.
Also, it is trading at rather expensive levels at just over 3.53x price/book and 1.74x price/sales. Compared to others, Conatus Pharmaceuticals Inc. is in a different league with regards to profitability, having net margins of -52.8%. To put some perspective around this, the industry’s average net margin is -697.14%. CNAT’s ROE is -84%, which is also considerably worse than the industry’s ROE of 0.93%. It’s also very liquid in the near term, with a current ratio of 2.4. The stock has a debt/capital of 0.
Shares of Conatus Pharmaceuticals Inc. (CNAT) have gained 5.1% since the company’s last earnings report. Over the past 12 fiscal quarters, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has topped consensus earnings estimates in 5 quarters (41%), missed earnings in 3 quarters (25%), whereas at 4 occasion EPS met analyst expectations. Revenue for the recent quarter stood at $7.67 million, down -20% on last year and below the $9.78 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $6.12 million to $10 million, which should be compared with $10.5 million generated last year. EPS is seen in a range of -$0.23 to -$0.09, against the -$0.13 reported a year ago.